| 注册
首页|期刊导航|中国药业|美托洛尔联合瑞舒伐他汀治疗老年冠心病并室性心律失常临床研究

美托洛尔联合瑞舒伐他汀治疗老年冠心病并室性心律失常临床研究

徐锋 陆叶

中国药业2024,Vol.33Issue(2):100-104,5.
中国药业2024,Vol.33Issue(2):100-104,5.DOI:10.3969/j.issn.1006-4931.2024.02.025

美托洛尔联合瑞舒伐他汀治疗老年冠心病并室性心律失常临床研究

Clinical Observation of Metoprolol Combined with Rosuvastatin in the Treatment of Elderly Coronary Heart Disease Complicated with Ventricular Arrhythmia

徐锋 1陆叶1

作者信息

  • 1. 江苏省江阴市人民医院,江苏 无锡 214400
  • 折叠

摘要

Abstract

Objective To investigate the clinical efficacy of metoprolol combined with rosuvastatin in the treatment of elderly coronary heart disease(CHD)complicated with ventricular arrhythmia.Methods A total of 98 elderly patients with CHD and ventricular arrhythmia admitted to the hospital from January 2020 to February 2023 were selected and divided into the observation group and the control group by the random number table method,with 49 cases in each group.The patients in the two groups were given basic treatments(diuretics,vasodilators,anti-platelet aggregation drugs)and Rosuvastatin Calcium Tablets(orally),on this basis,the patients in the observation group were given Metoprolol Succinate Sustained-Release Tablets(orally).Both groups were treated continuously for three months.Results The total effective rate in the observation group was 95.92%,which was significantly higher than 81.63%in the control group(P<0.05).Compared with those before treatment,the frequencies of ventricular premature beat,paired ventricular premature beat and short-term paroxysmal ventricular tachycardia in the two groups significantly decreased after treatment,the left ventricular ejection fraction(LVEF)significantly increased,the left ventricular end-diastolic diameter(LVEDd)and left ventricular end-systolic diameter(LVESd)significantly shortened(P<0.05).Compared with those before treatment,the vascular endothelial growth factor(VEGF)and nitric oxide(NO)levels in the two groups significantly increased after treatment,the endothelin-1(ET-1),soluble growth stimulation expressed gene 2 protein(sST2),cardiac troponin I(cTnI)and N-terminal pro-brain natriuretic peptide(NT-proBNP)levels significantly decreased(P<0.05).Compared with those before treatment,the tumor necrosis factor-α(TNF-α),myeloperoxidase(MPO),hypersensitive C-reactive protein(hs-CRP),low density lipoprotein cholesterol(LDL-C),triglyceride(TG)and total cholesterol(TC)levels in the two groups significantly decreased after treatment,and the high density lipoprotein cholesterol(HDL-C)level significantly increased(P<0.05).Compared with that before treatment,the Visual Analogue Scale(VAS)score of the European Quality of Life Five Dimension 3 level(EQ-5D-3L)in the two groups significantly increased after treatment(P<0.05).The above indexes in the observation group showed greater improvement(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(12.24%vs.10.20%,P>0.05).Conclusion Metoprolol combined with rosuvastatin in the treatment of elderly CHD complicated with ventricular arrhythmia can decrease the frequency of ventricular arrhythmia,improve cardiac function,vascular endothelial function and blood lipid levels,inhibit myocardial injury and inflammatory reaction,and improve patients'quality of life.

关键词

美托洛尔/瑞舒伐他汀/冠状动脉粥样硬化性心脏病/室性心律失常/老年患者/临床疗效

Key words

metoprolol/rosuvastatin/coronary heart disease/ventricular arrhythmia/elderly patient/clinical efficacy

分类

医药卫生

引用本文复制引用

徐锋,陆叶..美托洛尔联合瑞舒伐他汀治疗老年冠心病并室性心律失常临床研究[J].中国药业,2024,33(2):100-104,5.

基金项目

江苏省老年健康科研项目[LD2021034]. ()

中国药业

OACSTPCD

1006-4931

访问量0
|
下载量0
段落导航相关论文